PURPOSE: O-(2-[(18)F]Fluoroethyl)-L-tyrosine ((18)F-FET) is a well-established PET tracer for the imaging of cerebral gliomas, but little is known about (18)F-FET uptake in meningiomas. The aim of this study was to explore (18)F-FET kinetics and tumour-to-background contrast in meningiomas of various histologies. METHODS: A group of 24 patients with suspected cerebral meningioma on MRI/CT had an additional dynamic (18)F-FET PET scan prior to surgery. Time-activity curves (TAC) of (18)F-FET uptake in the tumours and tumour-to-brain ratios (TBR) for early (3 - 14 min after injection) and late (18)F-FET uptake (20 - 40 min after injection) were analysed and compared with histological subtypes and WHO grade. (18)F-FET uptake in critical structures in the skull base was also evaluated in terms of tumour-to-tissue (T/Tis) ratio. RESULTS: TBR of (18)F-FET uptake in meningiomas was significantly higher in the early phase than in the late phase (3.5 ± 0.8 vs. 2.2 ± 0.3; P < 0.001). The difference in TBR between low-grade meningiomas (WHO grade I, 18 patients) and high-grade meningiomas (WHO grade II or III, 6 patients) was significant in the late phase of (18)F-FET uptake (2.1 ± 0.2 vs. 2.5 ± 0.2, P = 0.003) while there was no significant difference in the early phase. ROC analysis showed that TBR of (18)F-FET uptake in the late phase had significant power to differentiate low-grade from high-grade meningiomas (AUC 0.87 ± 0.18, sensitivity 83 %, specificity 83 %, optimal cut-off 2.3; P < 0.01). Evaluation of TAC yielded three different curve patterns of (18)F-FET PET uptake. Combination of TBR (cut-off value 2.3) and TAC pattern slightly improved the differentiation of high-grade from low-grade meningiomas (accuracy 92 %; P = 0.001). Analysis of background radioactivity in the skull base indicated that (18)F-FET uptake may be helpful in distinguishing meningioma tissue in the late phase. T/Tis ratios were >1.2 in all patients for the periorbita, sphenoidal sinus, pituitary gland, tentorium, bone and brain, in more than 90 % of patients for the mucosa and dura, but in only 63 % of patients for the cavernous sinus. CONCLUSION: (18)F-FET PET may provide additional information for noninvasive grading of meningiomas and possibly for the discrimination of tumour in critical areas of the skull base. A further evaluation of (18)F-FET PET in meningiomas appears to be justified.
PURPOSE:O-(2-[(18)F]Fluoroethyl)-L-tyrosine ((18)F-FET) is a well-established PET tracer for the imaging of cerebral gliomas, but little is known about (18)F-FET uptake in meningiomas. The aim of this study was to explore (18)F-FET kinetics and tumour-to-background contrast in meningiomas of various histologies. METHODS: A group of 24 patients with suspected cerebral meningioma on MRI/CT had an additional dynamic (18)F-FET PET scan prior to surgery. Time-activity curves (TAC) of (18)F-FET uptake in the tumours and tumour-to-brain ratios (TBR) for early (3 - 14 min after injection) and late (18)F-FET uptake (20 - 40 min after injection) were analysed and compared with histological subtypes and WHO grade. (18)F-FET uptake in critical structures in the skull base was also evaluated in terms of tumour-to-tissue (T/Tis) ratio. RESULTS:TBR of (18)F-FET uptake in meningiomas was significantly higher in the early phase than in the late phase (3.5 ± 0.8 vs. 2.2 ± 0.3; P < 0.001). The difference in TBR between low-grade meningiomas (WHO grade I, 18 patients) and high-grade meningiomas (WHO grade II or III, 6 patients) was significant in the late phase of (18)F-FET uptake (2.1 ± 0.2 vs. 2.5 ± 0.2, P = 0.003) while there was no significant difference in the early phase. ROC analysis showed that TBR of (18)F-FET uptake in the late phase had significant power to differentiate low-grade from high-grade meningiomas (AUC 0.87 ± 0.18, sensitivity 83 %, specificity 83 %, optimal cut-off 2.3; P < 0.01). Evaluation of TAC yielded three different curve patterns of (18)F-FET PET uptake. Combination of TBR (cut-off value 2.3) and TAC pattern slightly improved the differentiation of high-grade from low-grade meningiomas (accuracy 92 %; P = 0.001). Analysis of background radioactivity in the skull base indicated that (18)F-FET uptake may be helpful in distinguishing meningioma tissue in the late phase. T/Tis ratios were >1.2 in all patients for the periorbita, sphenoidal sinus, pituitary gland, tentorium, bone and brain, in more than 90 % of patients for the mucosa and dura, but in only 63 % of patients for the cavernous sinus. CONCLUSION: (18)F-FET PET may provide additional information for noninvasive grading of meningiomas and possibly for the discrimination of tumour in critical areas of the skull base. A further evaluation of (18)F-FET PET in meningiomas appears to be justified.
Authors: Ali Afshar-Oromieh; Frederik L Giesel; Heinz G Linhart; Uwe Haberkorn; Sabine Haufe; Stephanie E Combs; Dino Podlesek; Michael Eisenhut; Clemens Kratochwil Journal: Eur J Nucl Med Mol Imaging Date: 2012-06-05 Impact factor: 9.236
Authors: Jan Frederick Cornelius; Karl Josef Langen; Gabriele Stoffels; Daniel Hänggi; Michael Sabel; Hans Jakob Steiger Journal: Neurosurgery Date: 2012-04 Impact factor: 4.654
Authors: Anca-Ligia Grosu; Wolfgang A Weber; Sabrina T Astner; Markus Adam; Bernd J Krause; Markus Schwaiger; Michael Molls; Carsten Nieder Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-09 Impact factor: 7.038
Authors: Martha Nowosielski; Norbert Galldiks; Sarah Iglseder; Philipp Kickingereder; Andreas von Deimling; Martin Bendszus; Wolfgang Wick; Felix Sahm Journal: Neuro Oncol Date: 2017-11-29 Impact factor: 12.300
Authors: Michael Sommerauer; Jan-Karl Burkhardt; Karl Frontzek; Elisabeth Rushing; Alfred Buck; Niklaus Krayenbuehl; Michael Weller; Niklaus Schaefer; Felix P Kuhn Journal: Neuro Oncol Date: 2016-02-09 Impact factor: 12.300
Authors: Edit Bosnyák; David O Kamson; Anthony R Guastella; Kaushik Varadarajan; Natasha L Robinette; William J Kupsky; Otto Muzik; Sharon K Michelhaugh; Sandeep Mittal; Csaba Juhász Journal: Neuro Oncol Date: 2015-06-18 Impact factor: 12.300
Authors: Norbert Galldiks; Nathalie L Albert; Michael Sommerauer; Anca L Grosu; Ute Ganswindt; Ian Law; Matthias Preusser; Emilie Le Rhun; Michael A Vogelbaum; Gelareh Zadeh; Frédéric Dhermain; Michael Weller; Karl-Josef Langen; Jörg C Tonn Journal: Neuro Oncol Date: 2017-11-29 Impact factor: 12.300
Authors: K Mariam Slot; Dagmar Verbaan; Dennis R Buis; Linda J Schoonmade; Bart N M Berckel; W Peter Vandertop Journal: J Neuroimaging Date: 2020-11-02 Impact factor: 2.486
Authors: Norbert Galldiks; Frank Angenstein; Jan-Michael Werner; Elena K Bauer; Robin Gutsche; Gereon R Fink; Karl-Josef Langen; Philipp Lohmann Journal: Brain Pathol Date: 2022-03 Impact factor: 6.508